Objective: To compare two widely used permanent prostate brachytherapy techniques, preplanning and intraoperative planning, based on postimplant dosimetry, toxicity and biochemical outcomes. Methods: Between 2003 and 2006, 665 men with localized prostate cancer were treated with permanent interstitial implantation. The first 227 consecutive men were treated with the preplanning technique, followed by 438 men treated with the intraoperative technique. Late toxicity was scored by the Common Terminology Criteria for Adverse Events v.4.0. Biochemical failure was defined as a prostate-specific antigen increase of more than 2 ng/ml above the nadir value excluding a benign bounce. Univariate and multivariate analyses were performed to identify the variables associated with biochemical failure-free survival. Results: Postimplant target coverage was similar in the two groups, with a small difference in risk organ doses. Mean V100 was 96.3 vs. 96.7% (P ¼ 0.205), D90 was 119.6 vs. 119.4% (P ¼ 0.884), urethral D10 was 157.5 vs. 146.1% (P ¼ 0.010), rectal V100 was 0.57 vs. 0.43 cc (P ¼ 0.002) in the preplanning and intraoperative planning groups, respectively. Acute and late Grade 3 genitourinary and gastrointestinal toxicities were ,1% for both methods. The 5-year biochemical failure-free survival rate was 95.4% for the preplanning and 94.0% for the intraoperative planning group (P ¼ 0.776). Multivariate analysis revealed Gleason score, biopsy positive rate and V100 to be predictors of biochemical failure-free survival, while the planning technique was not significant. Conclusion: This large-scale analysis of high-quality implants revealed similar postimplant dosimetry, toxicity profiles and biochemical failure-free survival for the preplanning and intraoperative planning methods.
INTRODUCTION
Permanent prostate brachytherapy (PPB) is now an established modality in the treatment of localized prostate cancer, with several long-term studies demonstrating biochemical control rates similar to those obtained by radical prostatectomy and external beam radiation therapy (EBRT) (1, 2) . The concept of delivering high radiation doses to the prostate while sparing normal tissues makes brachytherapy an attractive treatment option. There are currently two major approaches to brachytherapy: preplanning and intraoperative planning.
Traditionally, PPB implants were preplanned. With this technique, the patient is implanted according to a predetermined arrangement of seeds based on an ultrasound volume study performed several weeks in advance. Creation of a plan well before the actual procedure allows ample time to perform the necessary optimizations, and enables precise ordering of the seeds (3) . However, factors such as neoadjuvant hormonal therapy, difficulty in replication of the patient set-up, relaxation of the pelvic musculature during anesthesia and edema subsequent to needle and seed insertion can all lead to alterations of prostate volume and shape (4, 5) . While advocates of the preplanning method assert that these are nominal obstacles easily overcome with experience and minor intraoperative adjustments, some investigators have moved toward developing a single-step procedure, bringing the entire planning and implantation process into the operating room (6, 7) . The intraoperative method is supported by those who claim facilitated and enhanced accuracy in plan execution (8) . However, it also has drawbacks, as the need for a preoperative volume study is not completely eliminated, and costly operating room time may be prolonged.
Numerous institutions specializing in either the preplanning or the intraoperative method have demonstrated similar postimplantation dosimetry and excellent biochemical results. However, there are few reports directly comparing the clinical manifestations associated with these two methods (9 -11) . Moreover, to our knowledge, details from a large-scale cohort study have not previously been reported. The purpose of this study was to provide a single-institution comparison of preplanning and intraoperative planning based on postimplant dosimetry, toxicity and biochemical outcomes. 10 and Gleason score 3 þ 4 with biopsy positive core rate ,1/3) patients were also given monotherapy. The prescription dose was 145 Gy to the planning target volume (PTV) for brachytherapy alone and 100 Gy for combined modality therapy. Hormonal therapy was administered frequently, either as a leutenizing hormone, anti-androgen or both. Because Japanese national policy for patient discharge criteria mandates that total seed activity be kept below 1300 MBq, patients with prostate volumes .45 cc usually must undergo hormonal therapy to down-size the prostate prior to implantation. All procedures were conducted utilizing I-125 free seeds.
PATIENTS AND METHODS

PREPLANNING TECHNIQUE
Our implantation procedure, based on the Seattle technique, has been previously described in detail (12) . Briefly, a preplanning session was scheduled 4 weeks before the actual implant procedure. Consecutive transverse images of the prostate were obtained at 5 mm intervals and imported into a dedicated treatment planning system (Variseed version 7.0, Varian Medical Systems, Inc., Palo Alto, CA, USA). The prostate was expanded to a PTV by adding a 3 mm margin in all directions except the posterior rectal interface, where no margin was added. A plan containing needle locations, number and seed strength was generated. Preplan dosimetry aimed for .90% volume of the prostate receiving 100% of the prescription dose (V100 . 90%), the minimum dose received by 90% of the prostate volume .100% of the prescription dose (D90 . 100%), V150 , 50% and V200 , 25%. Doses covering 30% of the urethral volume (uD30) and 30% of the rectal volume (rD30) were to be limited to ,130 and ,80% of the prescription dose, respectively. The actual implantation procedure was executed according to the preplan using a Mick applicator (Mick Radio-Nuclear Instruments, Inc., Mount Vernon, NY, USA) to individually load the seeds.
INTRAOPERATIVE TECHNIQUE
Our intraoperative technique, based on the Mt. Sinai approach, was also previously described (13) . Briefly, instead of a preplan, a standard look-up nomogram based on a preoperative volume study was used to identify the activity needed to ensure adequate PTV coverage. The number of seeds to be ordered was determined by dividing the total activity by the activity per seed, plus a few extra seeds. An optimized treatment plan was then created in the brachytherapy unit on the day of the implant, defining the prostate itself as the PTV. Dose constraints included V100 . 95%, V150 , 50%, D90 110 -130%, urethral volume receiving 150% of the prescription dose (uV150) ,0.1 cc and rectal volume receiving 100% of the prescription dose (rV100) ,0.1 cc.
384
Planning methods for prostate brachytherapy
POSTOPERATIVE CT DOSIMETRY
Postimplant CT studies at 3 mm intervals were obtained for all patients at 1 month (Day 30) after the procedure. Urethral locations on Day 30 images were estimated by referring to the locations on intraoperative US images displayed on an adjacent workstation. A single investigator (A.Y.) contoured the prostate, urethra and rectal circumferences, viewing each as a whole organ. Dose-volume histograms were generated for the target and surrounding normal tissue structures. Parameters evaluated included V100, V150, D90, uD10 and rV100.
ENDPOINTS AND STATISTICAL ANALYSIS
Median follow-up was 76 months (range: 6 -84) for the preplanning group and 55 months (range: 12 -70) for the intraoperative group. Acute toxicity was considered to be symptoms developing within the first year after implantation. Late toxicity was defined as any symptom developing after the first year, or symptoms that developed during the first year and persisted 12 months. Late toxicity was scored by the Common Terminology Criteria for Adverse Events v.4.0. Biochemical failure was defined as a PSA increase to more than 2 ng/ml above the nadir value. Patients meeting the criteria for biochemical failure, but showing a subsequent decrease to ,0.5 ng/ml without intervention were classified as having a benign bounce, and were excluded from the analysis of failure. x 2 testing was used for categorical parameters. Actuarial survival curves were calculated by the Kaplan-Meir method, with differences between time-adjusted rates evaluated with the log-rank test. Cox-proportional hazards multivariate analysis was used to assess the influences of different covariates on the results. Variables showing an association in univariate analysis (P 0.10) were included in the multivariate analysis. Analyses were carried out using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). All tests were two-sided, and statistical significance was set at the level of P , 0.05.
RESULTS
Preimplant patient characteristics and plan-related parameters are shown in Tables 1 and 2 . The intraoperative planning group includes a larger percentage of patients with Gleason's score 7 (58.1 vs. 27.6%) accounting for a greater percentage of the NCCN intermediate risk group (62 vs. 49%) than the preplanning group. However, because low-tier, intermediate-risk group patients as of 2005 were assigned to receive monotherapy, only slightly more patients received supplemental EBRT in the intraoperative planning group (54.5 vs. 45.5%). The preplanning group contained more patients receiving neoadjuvant hormonal therapy due to longer waiting times during the preliminary period.
Postimplant dosimetric comparisons for target coverage and normal tissue structures are shown in Table 3 . Mean V100 and D90 were strikingly similar in the two groups. Slightly better sparing of urethral and rectal structures was observed in the intraoperative planning group, and the difference did reach statistical significance. On the other hand, the 
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incidences of urinary and rectal morbidity differed minimally between the two groups (Table 4) . Biochemical failure-free survival (BFFS) rates for both groups are shown in Fig. 1 . The 5-year BFFS rate was 95.4% for the preplanning group and 94.0% for the intraoperative planning group, with no significant difference (P ¼ 0.776).
Univariate analysis including age, clinical stage, PSA, Gleason score, biopsy positive core rate, supplemental EBRT use, hormone administration, planning technique, planned ultrasound target volume (PUTV) and V100 was conducted to test for predictors of BFFS. Only Gleason score, biopsy positive core rate and V100 were significant factors, and all three remained significant on multivariate analysis (Table 5 ).
DISCUSSION
Brachytherapy is now an established modality in the treatment of localized prostate cancer. Although the debate continues over which method, preplanning or intraoperative planning, is better suited to consistently achieve high-quality implants, proponents of both methodologies have reported excellent dosimetry and clinical results. However, few institutions have directly compared these two implant techniques.
Zelefsky et al. (9) reported the dosimetric outcomes and acute toxicity profiles in 248 patients receiving intraoperative planning, and compared the results with those of a historical cohort of 247 patients treated by a CT-based preplanning method. Median V100 was 96 vs. 88%, the urethral mean was 140 vs. 263% and the maximum urethral dose was 170 vs. 532% for the intraoperative and preplanning groups, respectively. Significantly lower urethral doses resulted in a reduced incidence of acute urinary retention (8 vs. 14%), and the time to resolution of symptoms was shorter. The incidences of Grade 2 or more severe acute and late rectal toxicities were 3 and 6.5% vs. 3 and 8%, not statistically significant differences. They concluded that intraoperative planning allowed for better target coverage and sparing of normal tissues.
Shah et al. (10) compared 42 patients who received preoperative preplanning with 93 patients who underwent intraoperative preplanning. The 4-year BFFS rate was 82% for the preoperative vs. 96% for the intraoperative preplanning group. They attributed this superior disease control, at least in part, to improved dosimetric target coverage, with 4 -5-week postimplant dosimetry revealing D90 of 75 vs. 90% and V100 of 76 vs. 83%, respectively, for the preoperative and intraoperative groups. Planning method was the only predictor of disease control in multivariate analysis with the covariates of pretreatment PSA, Gleason score, clinical stage and case sequence number.
Matzkin et al. (14) prospectively compared 142 consecutive men treated by the preplanning method with 214 men treated by the intraoperative method. Dosimetry based on Day 30 postimplant CT revealed mean D90, V100 and V150 to be 53, 58.35 and 21.5% vs. 114, 95.2 and 45% for the preplanning and intraoperative planning groups, respectively. They hypothesized that difficulty in patient set-up and replication of treatment plan in the preplanning group led to the discrepancy in results. Biochemical outcomes at 48 months for 75 monotherapy patients in the preplanning and 105 in the intraoperative group revealed 96% of patients in the intraoperative group to have nadir values ,0.5 ng/ml, when compared with only 56% in the (9) preplanning group (P , 0.0001) (11). V150 and V100, the percent volume of the postimplant prostate receiving 150 and 100% of the prescribed dose, respectively; D90, the minimum dose received by 90% of the prostate volume; uD10, doses covering 10% of the urethral volume; rV100, the rectal volume receiving 100% of the prescription dose. 
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The few institutions reporting experience with both methods have generally obtained suboptimal results with the preplanning method, suggesting the superiority of the intraoperative approach. However, these numbers in no way compare with those from the leading preplanning centers. Merrick et al. (15) reported Day 0 dosimetry with a median V100 of 95%, V150 of 51%, D90 of 160 Gy and median urethral dose of 118%. Grimm et al. (16) reported Day 1 dosimetry with a median V100 of 91%, V150 of 49% and D90 of 145 Gy. In terms of biochemical control, Sylvester et al. (17) described their early experience in 215 prospectively followed patients treated with I-125 monotherapy. The 15-year BFFS rates were 85.9, 79.9 and 62.2% for low-, intermediate-and high-risk patients, respectively. Crook et al. (18) published 7-year BFFS results of 95.2% for 1100 patients using the Seattle-based preplanning approach and 18 .5% of patients experiencing late Grade 2 and 1.3% Grade 3 genitourinary (GU) toxicity among 165 patients undergoing intraoperative inverse optimization. Our late Grade 2 -3 GU toxicity rate was 7.5% with the preplanning method and 6% with the intraoperative planning method, with only one patient in each group experiencing Grade 3 toxicity. These numbers are at least as good, if not better, than some of the best data reported in the literature.
A difference in urinary morbidity has also been attributed to the use of radioactive strands vs. free seeds. Fagundes et al. (24) , in a comparison of 337 patients treated with the preplanned free seed technique and 136 receiving stranded seeds, noted a lower urinary V150 dose of 2.8% with free seeds vs. 9.7% with stranded seeds. The difference in dosimetry translated into lower rates of acute urinary retention, 2.9 vs. 8.9% (P ¼ 0.01), respectively. Our acute urinary retention rate of 6.1% in the preplanned group and 5.5% with intraoperative planning appear to be reasonable considering that all implantations were conducted with free seeds.
It is interesting to note that both uD10 and rV100 were significantly lower in the intraoperative planning group. Although this did not translate into a significantly reduced incidence of GU and gastrointestinal (GI) toxicity between the two groups, a modest reduction was seen for all analyzed parameters, excepting late Grade 3 GU toxicity. Whether these differences are indicative of a trend needs to be confirmed with longer follow up.
CONCLUSION
This large-scale comparison of high-quality implants revealed no significant difference in biochemical outcomes or toxicity profiles between the two widely used techniques: preplanning and intraoperative planning. Our results suggest that with meticulous attention to detail, high-quality implants can be performed with either method. Long-term follow up is needed to further clarify these results.
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